



Supplementary Figure 1. MT1-MMP deficiency suppresses the release of sACE2 in kidney epithelial cells

(a) Western blotting analyses on the expression of ACE2 in wild-type (WT) and *Mmp14*^{-/-} mouse primary kidney epithelial cells. The level of soluble ACE2 (solACE2) was detected in conditioned media. Coomassie stained membrane was a loading control for conditioned medium. (n=3) **(b)** Western blotting analyses on the levels of solACE2 and memACE2 in Huh-7 and CaCo2 cells transfected with either control siRNA or siMMP14. (n=3)




Supplementary Figure 2. Physical interaction between MT1-MMP and ACE2

(a) Western blotting analyses on the levels of memACE2 in the total cell lysate (TCL) and solACE2 in the conditioned media (CM) derived from ACE2-expressing HEK293T cells transfected with plasmids expressing different MMPs including MT1-MMP, MMP2, MMP9 and MMP13. Coomassie stained membrane served as a loading control for conditioned media. (n=3) **(b)** HEK-293T cells were cotransfected with ACE2-GFP and MT1-MMP-FLAG plasmids. Cell lysates were subjected to immunoprecipitation with the indicated antibodies, followed by western blotting analyses. (n=3) **(c)** Recombinant ACE2 protein was incubated with MT1-MMP derived from the lysate of HEK293T cells transfected with plasmid expressing MT1-MMP, followed by the immunoprecipitation with the anti-ACE2. The expression of MT1-MMP was detected in the ACE2 immunoprecipitate by western blotting. (n=3)



Supplementary Figure 3. The identification of MT1-MMP cleavage site of ACE2


(a) S707A mutation abolished the ACE2 shedding by MT1-MMP. 293T cells were co-transfected with MT1-MMP and different ACE2 mutants including wild-type ACE2, ACE2^{I727A}, ACE2^{L725A}, ACE2^{S709A}, ACE2^{S707A} and ACE2^{L675A}. The levels of memACE2 in total cell lysate (TCL) and solACE2 in conditioned media (CM) were detected by western blotting. Coomassie stained membrane served as a loading control for conditioned media. (n=3) **(b)** The physical interaction between MT1-MMP and ACE2^{S707A} was examined by co-immunoprecipitation using the cell lysates derived from HEK293T cells co-expressing MT1-MMP and ACE2^{S707A}. (n=3) **(c)** Immunofluorescent staining of ACE2 in HEK293T cells with ectopic expression of either wild-type ACE2 or ACE2^{S707A}. (n=3) (scale bars: 20 μ m)




Supplementary Figure 4. Mass-spectrometry analyses of ACE2 fragment

(a) Recombinant ACE2 was cleaved by recombinant catalytic domain of MT1-MMP (cMT1) in the in vitro cleavage assay, following by SDS-PAGE. The protein bands in the gel were visualized by Coomassie blue staining. The ACE2 truncated fragment generated by MT1-MMP cleavage, indicated by the black arrow, was sequenced by mass spectrometry (MS) analyses followed by tandem MS/MS as shown in (b). (n=3)


ACE2(691-710)




ACE2(691-710) + cMT1




ACE2(691-710) + cMT1 + EDTA




ACE2(701-720)



ACE2(701-720) + cMT1




ACE2(701-720) + cMT1



Supplementary Figure 5. Identification of MT1-MMP cleavage site of ACE2 by mass-spectrometry


Mass spectrometry analysis of ACE2 peptides 691^V-710^R and 701^E-720^N after incubation with the catalytic domain of MT1-MMP. Control experiments were performed in the presence of EDTA. In the presence of recombinant MT1-MMP, the intact peptide 691^V-710^R was cleaved into a smaller fragment that was identified as VSDIIPRTEVEKAIRM by tandem MS/MS. Consistently, the intact peptide 701^E-720^N was digested into two smaller fragments that were identified as EKAIRM and SRSRINDAFGLNDN respectively. MT1-MMP cleaved both peptides at M706-S.



Supplementary Figure 6. sACE2 released by MT1-MMP mediates cell entry of SARS-CoV-2 through AT1R


(a) Conditioned media derived from HEK-293T cells co-transfected with/without ACE2 and MT1-MMP were incubated with recombinant spike proteins of SARS-CoV-2. Subsequently, the protein complex was immunoprecipitated with spike-specific antibodies and were analyzed by western blotting using specific antibodies. (n=3) (b) Caco2 cells were firstly transduced with adenoviral vector of MT1-MMP and then transfected with siRNAs targeting either AT1 or AVPR1B, followed by the infection with SARS-CoV-2 pseudotyped virus. Luciferase levels were detected at 72 h post-infection. (n=3 biologically independent experiments) (c) Immunofluorescent staining of SARS-CoV-2 spike protein, solACE2 and AT1-transfected 293T cells. Non-permissive HEK293T cells were firstly

transfected with GFP-tagged AT1 and then inoculated with recombinant SARS-CoV-2 spike protein along with conditioned media derived from 293T cells expressing ACE2 only or ACE2 with MT1-MMP. The cells were immunostained with anti-S (purple) and anti-ACE2 antibodies (red), and counterstained with DAPI to label nuclei (blue). (scale bars: 20 μ m) (n=3 biologically independent experiments) **(d)** HEK293T cells were firstly transfected with AT1R-GFP and then inoculated with the HEK293T conditioned media containing recombinant SARS-CoV-2 spike proteins and solACE2 released by MT1-MMP. The protein complex of AT1R-GFP was purified by immunoprecipitation, followed by western blotting analyses on the expression of spike proteins and ACE2. (n=3) The data are shown as the means \pm SEM from three independent experiments. P values were calculated using one-way ANOVA for **(b)**. Source data are provided as a Source Data file.




Supplementary Figure 7. Validation of MT1-MMP knockdown in primary culture

(a-d) qPCR analyses on the mRNA expression of MT1-MMP in human bronchial epithelial cells **(a)** (n=3 biological independent experiments), primary human bronchial epithelial 3D cultures with an air-liquid interface (ALI) **(b)** (n=3 biological independent experiments), human cardiac organoids formed by iPSC-derived cardiomyocytes **(c)** (n=3 biological independent experiments) and human liver organoids **(d)** (n=3 biological independent experiments) after lentiviral transduction with shRNA or shMMP14. The data are shown as the means \pm SEM. unpaired two-tailed *t*-test for **(a-d)** Source data are provided as a Source Data file.



Supplementary Figure 8. Tissue distribution of AAV transduction in mice


(a) qPCR analyses of the expression of human ACE2 in mice expressing *solACE2₁₋₇₀₆/ solACE2₁₋₇₄₀/ACE2 (full length)*. (n=7 for AAV-control; n=7 for AAV-hACE2(1-706); n=6 for AAV-hACE2 (1-740)). **(b)** The level of human ACE2 in the plasma from mice expressing *solACE2₁₋₇₀₆/ solACE2₁₋₇₄₀* was measured by ELISA assay (n=7 for AAV-control; n=7 for AAV-hACE2(1-706); n=6 for AAV-hACE2 (1-740)). The data are shown as the means \pm SEM. Source data are provided as a Source Data file.



Supplementary Figure 9. solACE2 facilitates SARS-CoV-2 infection in non-permissive laboratory mice


(a) The number of viral antigen-presenting cells in lung sections of mice (50 \times field) expressing solACE2₁₋₇₀₆/ solACE2₁₋₇₄₀/ACE2_{full length (FL)} (n=8 for AAV-control; n=8 for AAV-hACE2(1-706); n=8 for AAV-hACE2 (1-740); n=8 for AAV-hACE2(full length)). **(b)** qPCR analyses of inflammatory cytokines including IL-6, IL-1 β , Cxcl10 and IFN- γ were performed in lung tissues of mice expressing

solACE2₁₋₇₀₆/ solACE2₁₋₇₄₀/ACE2_{full length (FL)} (n=8 for AAV-control; n=8 for AAV-hACE2(1-706); n=8 for AAV-hACE2 (1-740); n=8 for AAV-hACE2(full length)). The data are shown as the means \pm SEM. One-way ANOVA for **a-b**. Source data are provided as a Source Data file.




Supplementary Figure 10. MT1-MMP knockdown suppresses solACE release and the infection of SARS-CoV-2 variants of concern

(a) Primary human bronchial epithelial 3D cultures with an air-liquid interface (ALI) pre-treated with different concentrations of 3A2 were infected with SARS-CoV-2 wild-type strain. The levels of memACE2 in total cell lysate (TCL) and solACE2 in conditioned media (CM) were examined by western blotting. Coomassie stained membrane served as a loading control for conditioned media. (n=3) **(b-d)** CaCo2 cells were transfected with 5nM, 10nM or 30nM siMMP14 or control siRNA, followed by infection with SARS-CoV-2 wild-type strain **(b)**, SARS-CoV-2 delta variants **(c)** or SARS-CoV-2 omicron variants **(d)** (MOI=0.1) for 48 h. Viral infection were assayed by RT-qPCR for SARS-CoV-2 progeny titers. The data are shown as the means \pm SEM from three independent experiments. P values were calculated using one-way ANOVA. Source data are provided as a Source Data file.




Supplementary Figure 11. The upregulation of ACE2 and MT1-MMP in aged mice

Plasma levels of ACE2 (a) and MMP14 (b) in young and old mice were measured by ELISA. The data are shown as the means \pm SEM. $**p < 0.01$, unpaired two-tailed *t*-test. (n=5). Source data are provided as a Source Data file.




Supplementary Figure 12. 3A2 treatment protects aged mice from SARS-CoV-2 infection

(a) The number of viral antigen-presenting cells in lung and tracheal sections of 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 (n=5 for IgG control; n=6 for 3A2) (50× field) **(b)** Microarray analyses of inflammatory cytokines and chemokines in lung tissues from 3A2/control IgG-treated mice challenged with mouse-adapted SARS-CoV-2 (n=5 for IgG control; n=6 for 3A2) The data are shown as the means ± SEM. Unpaired two-tailed t-test for **(a)**. Source data are provided as a Source Data file.



Supplementary Figure 13. Comparison of ACE2 shedding by various proteases

HEK293T cells were co-transfected with ACE2 and either control, ADAM9, ADAM17 or MT1-MMP plasmids. The expression of ACE2 was examined in conditioned media and total cell lysates by western blotting using specific antibodies. Coomassie stained membrane served as a loading control for conditioned medium. (n=3)



Supplementary Figure 14. MT1-MMP does not process SARS-CoV-2 spike proteins

(a) HEK293T cells were transfected with plasmids expressing MT1-MMP and SARS-CoV-2 Spike derived from wild-type, delta and omicron variants, followed by western blotting analyses of spike expression. (n=3) **(b)** Recombinant SARS-CoV-2 Spike proteins derived from wild-type, delta and omicron variants were incubated with the catalytic domain of MT1-MMP (cMT1) *in vitro*, followed by western blotting analyses of spike levels. (n=3)

Supplementary Table 1 The primers for the ACE2 mutations were (5'-3'):

Mutation Sites	Forward	Reverse
L675A	GTGCGAGTGGCTAATGCGAAA CCAAGAATCTCC	GGAGATTCTTGGTTTCGCATT AGCCACTCGCAC
S707A	AAGGCCATCAGGATGGCCCGG AGCCGTATCAAT	ATTGATACGGCTCCGGGCCAT CCTGATGGCCTT
S709A	ATCAGGATGTCCCGGGCCCGT ATCAATGATGCT	AGCATCATTGATACGGGCCC GGGACATCCTGAT
L725A	AACAGCCTAGAGTTTGCGGGG ATACAGCCAACA	TGTTGGCTGTATCCCCGCAA CTCTAGGCTGTT
I727A	CTAGAGTTTCTGGGGGCACAG CCAACACTTGA	TCCAAGTGTGGCTGTGCCCC CAGAACTCTAG

Figure 1

Figure 1a




Figure 1c




Figure 1d




Figure 1e




Figure 1f




Figure 3




Figure 7



Figure S1

Figure S1a




Figure S1b




Figure S2

Figure S2a




Figure S2b




Figure S2c




Figure S3

Figure S3a




Figure S3b




Figure S6





Figure S10




Figure S13




Figure S14

